 |
Another Sterilizer Sale for TSO3March 27, 2006Québec City, March 27, 2006 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces another firm sale of its 125L Ozone Sterilizer.“We are quite pleased with this new addition to our base of customers,” said Ann Hewitt, Vice President of Sales and Marketing at TSO3 Inc. “This hospital is extremely well-regarded in its areas of specialization, and is located in a new geographic area for us, which will allow us to increase our market presence in a new part of the U.S.” TSO3’s sales and marketing department currently includes eight sales professionals along with five clinical specialists. TSO3 is in the recruiting process to add to this sales force during 2006 and has instituted a formal forecasting process that allows it to monitor the increase in its sales pipeline. “We see the sales pipeline growing at an accelerating rate”, says Jocelyn Vézina, CEO at TSO3 Inc. “We are very pleased with what we foresee in terms of sales for this year, as well as what is also out there for 2007 and 2008”. About TSO3 TSO3 Inc. is located in Québec City, Québec, Canada, and was founded in 1998. The Company’s mission is to develop and market innovative and comprehensive sterilization solutions. TSO3 has perfected an innovative sterilization process using ozone as the sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize heat and moisture-sensitive surgical and diagnostic devices which are expensive and in high demand from the surgical suite. The ozone sterilization process is a safe, efficacious, fast and cost-effective response to evolving sterilization needs. The 125L Ozone Sterilizer by TSO3 has been cleared for commercialization by Health Canada and by the U.S. Food and Drug Administration (FDA). TSO3 has sold its first sterilizer in Q4 2005. TSO3 currently has 54 employees, 16 of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications and Investor Relations Phone: (418) 651-0003, Ext. 237 Email: ccote@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
